Levocarnitine
Brand names: Carnitor
Levocarnitine (L-carnitine) is used to treat primary carnitine deficiency and carnitine depletion associated with certain metabolic disorders and dialysis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is the physiological form of carnitine that facilitates transport of long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation and energy production, and helps remove accumulated acyl groups.
Prescribing in practice
- Use the levo-isomer only, as the D-isomer can cause a myasthenia-like syndrome; ensure the correct preparation is prescribed.
- Oral dosing may cause gastrointestinal upset and a fishy body odour, which can be reduced by spreading doses through the day.
- It is available in oral and intravenous forms, with the route chosen according to indication and the ability to absorb oral therapy.
Monitoring
Monitor plasma carnitine concentrations and clinical response, adjusting therapy to maintain adequate levels.
Counselling the patient
- Take oral doses spread through the day, with or after food, to improve tolerance.
- A fishy body odour can occur and tends to lessen with dose adjustment.
- Continue treatment as directed for your metabolic condition.
Evidence & guidelines
Carnitine supplementation is the established treatment for primary carnitine deficiency and recognised carnitine-depletion states.
Reference: SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016